Kymriah genetically modified autologous T cells for infusion Images
Generic Name: tisagenlecleucel
This medication has been identified as Kymriah genetically modified autologous T cells for infusion and is used for Acute Lymphoblastic Leukemia, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma. It belongs to the drug class miscellaneous antineoplastics and is not a controlled substance.
Images of medication
Kymriah
- Generic Name
- tisagenlecleucel
- Strength
- genetically modified autologous T cells for infusion
- Availability
- Prescription only
- Drug Class
- Miscellaneous antineoplastics
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Novartis Pharmaceuticals Corporation
- National Drug Code (NDC)
- 00078-0846
See also:
More about Kymriah (tisagenlecleucel)
- Check interactions
- Compare alternatives
- Drug images
- Latest FDA alerts (3)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.